Lilly Drug Slows Alzheimer’s By 60%

USA – Eli Lilly’s experimental drug Donanemab slowed the progression of Alzheimer’s by 60% for patients in the earliest stages of the brain-wasting disease. That’s according to trial data presented at a medical meeting Monday.

The drug slowed cognitive decline by nearly twice the rate lilly reported in may for the trial’s overall treatment group.

The full analysis showed results were less robust for older, later-stage patients as well as those with higher levels of a protein linked to disease progression.